The largest and most influential international medical equipment exhibition, MEDICA 2024 in Germany, was held as scheduled. At this grand event, B&E made its appearance with a brand new booth in Hall 3, showcasing key products such as a handheld blood gas analyzer based on biosensor technology, an electrolyte analyzer, a 3/5-part differential hematology analyzer (including CRP/SAA combined test items using fluorescence immunoassay technology), and an HPLC gold standard HbA1c analyzer.

Focusing on the in vitro diagnostic field, B&E has continuously increased its R&D efforts, enriched its product line, and rapidly responded to customer needs for new products and professional after-sales services. This has earned the company widespread recognition in the international in vitro diagnostic sector, deepening its brand influence. Both new and old customers look forward to establishing long-term, mutually beneficial cooperation with the company.

The i-check handheld blood gas analyzer became the star product of B&E at this year's exhibition, attracting favor from clients around the world. The performance of the i-check product matches that of internationally renowned brands like Abbott's i-STAT and Siemens' e POC, particularly excelling in aspects such as card storage life, testing time, and card reliability, better meeting terminal users' special requirements for the timeliness, flexibility, and reliability of blood gas tests.

The KS series electrolyte analyzers were another highlight of B&E's exhibition lineup. Based on the CBS series products, the KS series adopt a direct method for total calcium measurement, with a testing speed exceeding 100 samples per hour. The truly maintenance-free long-life electrode technology further reduces the testing costs for end-users, providing high-quality and reliable solutions for hospitals with large sample volumes.

For a long time, B&E has steadily progressed in the blood cell analysis field, with over 5,000 units of 3/5-part differential hematology analyzers installed globally. Upholding the concept of continuous innovation, the company has added CRP/SAA combined test items using fluorescence immunoassay technology to its 5-part differential hematology analyzers, successfully offering more convenient and reliable diagnostic means for inflammation detection.

B&E successfully concluded this grand event, fully demonstrating its technical strength and brand image to international clients. The company will continue to increase investment in R&D, constantly enhance its independent innovation capabilities, further expand its international market presence, and strive to build itself into an internationally competitive in vitro diagnostic technology and innovative enterprise, providing more precise and reliable diagnostic products and solutions to global healthcare providers.